Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1184 participants
OBSERVATIONAL
2000-12-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Special Investigation of Kaletra in Pregnant Women
NCT01076985
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
NCT01328158
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
NCT01153269
Evaluation of Kaletra Therapy Over the Long-term
NCT01083810
Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients
NCT00234923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lopinavir/ritonavir group
All patients in this non-interventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
Lopinavir/ritonavir (Kaletra)
Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lopinavir/ritonavir (Kaletra)
Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with a history of hypersensitivity to any ingredient of Kaletra
* Patients who are receiving pimozide, cisapride, ergotamine tartrate, dihydroergotamine mesylate, ergometrine maleate, methylergometrine maleate, midazolam, triazolam, vardenafil hydrochloride hydrate, boriconazol
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yo Hoshino
Role: STUDY_DIRECTOR
Abbott Japan Co.,Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 36516
Aichi, , Japan
Site Reference ID/Investigator# 36517
Aichi, , Japan
Site Reference ID/Investigator# 36518
Chiba, , Japan
Site Reference ID/Investigator# 36519
Fukuoka, , Japan
Site Reference ID/Investigator# 36521
Fukuoka, , Japan
Site Reference ID/Investigator# 36522
Hiroshima, , Japan
Site Reference ID/Investigator# 36523
Hokkaido, , Japan
Site Reference ID/Investigator# 36524
Hyōgo, , Japan
Site Reference ID/Investigator# 36525
Kanagawa, , Japan
Site Reference ID/Investigator# 36526
Kyoto, , Japan
Site Reference ID/Investigator# 36622
Miyagi, , Japan
Site Reference ID/Investigator# 36623
Miyagi, , Japan
Site Reference ID/Investigator# 36624
Niigata, , Japan
Site Reference ID/Investigator# 36625
Okayama, , Japan
Site Reference ID/Investigator# 36626
Osaka, , Japan
Site Reference ID/Investigator# 36627
Osaka, , Japan
Site Reference ID/Investigator# 36628
Shizuoka, , Japan
Site Reference ID/Investigator# 36629
Tokyo, , Japan
Site Reference ID/Investigator# 36630
Tokyo, , Japan
Site Reference ID/Investigator# 36631
Tokyo, , Japan
Site Reference ID/Investigator# 36632
Tokyo, , Japan
Site Reference ID/Investigator# 36633
Tokyo, , Japan
Site Reference ID/Investigator# 36634
Tokyo, , Japan
Site Reference ID/Investigator# 36635
Tokyo, , Japan
Site Reference ID/Investigator# 36636
Tokyo, , Japan
Site Reference ID/Investigator# 36637
Tokyo, , Japan
Site Reference ID/Investigator# 36638
Tokyo, , Japan
Site Reference ID/Investigator# 36639
Tokyo, , Japan
Site Reference ID/Investigator# 5342
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMOS-JAP-00-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.